Investor Presentation for quarter and year ended March 31, 2026
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krsnaa Diagnostics reported strong FY25-26 results with revenue of Rs 7,728 million (up 8%) and PAT of Rs 1,013 million (up 31%). Full year EBITDA margin improved to 28% from 27% previously. Q4 PAT doubled year-on-year to Rs 417 million, though this includes a one-time fair valuation gain of Rs 221.75 million from Apulki Healthcare investment. The company operates 190 CT/MRI centres and 147 pathology labs across 18 states, completing 59 million+ tests. Rajasthan pathology expansion is underway targeting 249 satellite labs and 5,000+ collection centres. The retail segment (RPL brand) contributed 8% of revenue in Q4 FY26 vs 3% in Q4 FY25. Total borrowings increased significantly to Rs 4,905 million from Rs 1,655 million.
Strong profitability improvement and margin expansion are positive signals, though Q4 PAT was boosted by a one-time gain. The company has a substantial order book driving future network expansion. Increased debt levels warrant monitoring.